Cochrane Database Syst Rev

Almitrine bismesylate fdating

Treatment of hypoxemia during one-lung ventilation using intravenous almitrine. Almitrine-raubasine should not be co-prescribed with other preparations containing almitrine Vectarion. Treatment of the symptoms of neurosensory decline of ischemic origin in elderly patients, including visual and auditory deficit. In hypertensive patients, almitrine-raubasine does not replace specific antihypertensive treatment.

Shipped under ambient temperature as non-hazardous chemical. Treatment of tinnitus, vertigo and balance disorders of ischemic origin in elderly patients. Treatment of the symptoms of cognitive decline of ischemic origin in elderly patients. Stability-indicating methods for the determination of a mixture of almitrine and raubasine by derivative spectrophotometry.

Doppler study of the effects of inhaled nitric oxide and intravenous almitrine on regional pulmonary blood flows in patients with acute lung injury.

Low- vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. Weight loss, peripheral neuropathy with abnormal sensations in the lower limbs or paresthesiae prickling, pins-and-needles, numbness. Nausea, heartburns and epigastric heaviness, dyspepsia, disorders of the intestinal transit, sleep disorders eg, insomnia or drowsiness, agitation, anxiety, palpitations, vertiginous sensations. Cochrane Database Syst Rev.

Almitrine-Raubasine combination for dementia. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. Do not exceed the recommended dose.

Treatment of tinnitusShipped under ambient